1. "Melanoma and Immunotherapeutics Service"
Formats
  1. Journal Article (954)
  2. Meeting Abstract (771)
  3. Book Section (42)
  4. Editorial (32)
  5. Review (26)
  6. Research Letter (15)
  7. Guidelines (6)
  8. Correspondence (5)
  9. Conference Paper (4)
  10. Miscellaneous (3)
  11. Book Whole (2)
Groups
  1. Department of Medicine (1860)
  2. Melanoma and Immunotherapeutics Service (1860)
  3. Solid Tumor Oncology Division (1860)
  4. GSK Faculty (1050)
  5. Melanoma Disease Management Team (782)
  6. Hematologic Malignancies, Division of (507)

More Groups

People
  1. Jedd Wolchok (905)
  2. Taha Merghoub (364)
  3. Michael Postow (361)
  4. Paul Chapman (326)
  5. Alexander Shoushtari (244)
  6. Margaret Callahan (197)

More People

Years
  1. 2025 (22)
  2. 2024 (46)
  3. 2023 (66)
  4. 2022 (125)
  5. 2021 (112)
  6. 2020 (122)

More Years

Publications
  1. Journal of Clinical Oncology (330)
  2. Journal for ImmunoTherapy of Cancer (131)
  3. Cancer Research (106)
  4. Clinical Cancer Research (90)
  5. Annals of Oncology (77)
  6. Proceedings of the American Association for Cancer Research Annual Meeting (43)

More Publications

Publishers
  1. American Society of Clinical Oncology (342)
  2. American Association for Cancer Research (274)
  3. Biomed Central Ltd (148)
  4. Elsevier Inc. (144)
  5. Oxford University Press (109)
  6. Nature Publishing Group (88)

More Publishers

Results (1860)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Activating canonical p53 functions in tumor-associated macrophages improves immune checkpoint blockade efficacy
    Meeting Abstract

    Ghosh, A.; Michel, J.; Venkatesh, D.; Mezzadra, R.; Dong, L.; Samaan, F.; Gomez, R.; Suek, N.; Holland, A.; Ho, Y. J.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Phase II study of multiple LXH254 drug combinations in patients (pts) with unresectable/metastatic, BRAF V600-or NRAS-mutant melanoma
    Meeting Abstract

    Lebbe, C.; Long, G. V.; Robert, C.; Hamid, O.; Atkinson, V. G.; Shoushtari, A. N.; Daud, A.; Bechter, O. E.; Schadendorf, D.; Sullivan, R. J.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Long-term survivors on tebentafusp in phase II trial of previously treated patients with metastatic uveal melanoma
    Meeting Abstract

    Sato, T.; Ikeguchi, A. P.; Nathan, P.; Carvajal, R. D.; Shoushtari, A. N.; Gajewski, T. F.; Hassel, J. C.; Rioth, M.; Leyvraz, S.; Daniels, G. A.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • A phase I/II open-label study (IOV-GM1-201) of TALEN-mediated PD-1 inactivated autologous tumor-infiltrating lymphocytes (TIL; IOV-4001) in patients with advanced melanoma and NSCLC
    Meeting Abstract

    Chesney, J.; Wise-Draper, T.; Sarnaik, A. A.; Finckenstein, F. G.; Hari, P.; Jagasia, M.; Desai, A.; Suzuki, A.; Wu, X.; Warner, A. B.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Safety and efficacy of infrequent tebentafusp treatment omissions in patients with metastatic uveal melanoma
    Meeting Abstract

    Schlaak, M.; Dummer, R.; Kirkwood, J. M.; Joshua, A.; Milhem, M.; Gastaud, L.; Mauch, C.; Yushak, M. L.; Lockwood, S.; Hayes, C.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • A propensity score weighted comparison of tebentafusp or pembrolizumab versus combination ipilimumab and nivolumab in untreated metastatic uveal melanoma
    Meeting Abstract

    Piulats Rodriguez, J. M.; Piperno-Neumann, S.; Rutkowski, P.; Nathan, P.; Hassel, J. C.; Espinosa, E.; de la Cruz Merino, L.; Ochsenreither, S.; Shoushtari, A. N.; Orloff, M.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Results from phase I dose escalation of IMC-F106C, the first PRAME X CD3 ImmTAC bispecific protein in solid tumors
    Meeting Abstract

    Hamid, O.; Sato, T.; Davar, D.; Callahan, M. K.; Thistlethwaite, F.; Aljumaily, R.; Johnson, M. L.; Arkenau, H. T.; Ileana Dumbrava, E. E.; Izar, B.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Neutrophil phenotypes and functions in cancer: A consensus statement
    Review

    Quail, D. F.; Amulic, B.; Aziz, M.; Barnes, B. J.; Eruslanov, E.; Fridlender, Z. G.; Goodridge, H. S.; Granot, Z.; Hidalgo, A.; Huttenlocher, A.; more...
    Journal of Experimental Medicine (2022)

    Fulltext@MSK | Save
  • Ensuring equity in the era of HLA-restricted cancer therapeutics
    Editorial

    Smithy, J. W.; Blouin, A.; Diamond, L. C.; Postow, M.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Detectability of plasma-derived circulating tumor DNA panel in patients undergoing primary treatment for uveal melanoma
    Journal Article

    Francis, J. H.; Barker, C. A.; Brannon, A. R.; Canestraro, J.; Robbins, M.; Swartzwelder, C. E.; Levine, S.; Law, C.; Berger, M. F.; Shoushtari, A.; more...
    Investigative Ophthalmology & Visual Science (IOVS) (2022)

    Fulltext@MSK | Save